Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Operations (2019 - 2025)

Allogene Therapeutics' Cash from Operations history spans 7 years, with the latest figure at 29688000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 32.7% year-over-year to 29688000.0; the TTM value through Sep 2025 reached 158345000.0, up 27.13%, while the annual FY2024 figure was 200300000.0, 15.75% up from the prior year.
  • Cash from Operations for Q3 2025 was 29688000.0 at Allogene Therapeutics, up from 39030000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 29688000.0 in Q3 2025 and bottomed at 68237000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 49328000.0 (2021), against an average of 50790052.63.
  • The largest annual shift saw Cash from Operations tumbled 355.5% in 2021 before it soared 38.62% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 45436000.0 in 2021, then crashed by 36.67% to 62096000.0 in 2022, then grew by 13.51% to 53707000.0 in 2023, then surged by 31.67% to 36698000.0 in 2024, then rose by 19.1% to 29688000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Cash from Operations are 29688000.0 (Q3 2025), 39030000.0 (Q2 2025), and 52929000.0 (Q1 2025).